#USA #Chicago #Nuvalent #zidesamtinib #ARROS-1

Nuvalent Inc. to Present Key Findings on Zidesamtinib

Nuvalent, a clinical-stage biopharmaceutical company, is set to make a notable impact at the upcoming 2025 IASLC ASCO North America Conference on Lung Cancer, scheduled for December 5-7 in Chicago. The company plans to present significant patient-reported outcomes data alongside pivotal efficacy and safety data concerning Zidesamtinib, an investigational ROS1-selective inhibitor, during two dedicated poster presentations.

Conference Details

The first poster presentation will dive into the health-related quality of life and patient-reported outcomes from the Phase 2 segment of the ARROS-1 trial, specifically for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). The study examines the responses from both TKI pre-treated patients and those who are TKI-naïve. Dr. Melissa Laurie, Pharm.D., M.S., M.B.A., will serve as the presenting author for this session on December 6, from 4:00 to 5:30 PM ET.

The second presentation will introduce pivotal efficacy and safety data for Zidesamtinib in patients previously treated with tyrosine kinase inhibitors. This second abstract will be presented by Dr. Stephen V. Liu, M.D. during the same session time.

About Zidesamtinib and the ARROS-1 Trial

Zidesamtinib is a pioneering therapeutic candidate developed specifically as a brain-penetrant ROS1 inhibitor. This innovative approach aims to tackle the challenges and resistance mechanisms associated with currently available ROS1 inhibitors. Its design intends to ensure activity against tumors that have developed resistance, notably those with emerging ROS1 mutations, such as G2032R.

Furthermore, Zidesamtinib provides enhanced treatment options for patients suffering from brain metastases while avoiding the inhibition of the TRK family, thus minimizing CNS-related adverse effects commonly observed with dual TRK/ROS1 inhibitors.

The ARROS-1 trial (NCT05118789) represents a first-in-human Phase 1/2 clinical study targeting patients with advanced ROS1-positive NSCLC and other solid tumors. The Phase 1 component has been successfully completed, enrolling patients who had previously used at least one ROS1 TKI. This phase was primarily geared towards evaluating the safety and tolerability of Zidesamtinib, alongside determining the recommended Phase 2 dose, assessing pharmacokinetics, and reviewing preliminary anti-tumor activities.

The ongoing Phase 2 segment continues with the aim to provide regulatory insights and support the registration objectives for both TKI-naïve and TKI-pre-treated patients. In fact, Nuvalent has recently finalized its rolling NDA submission for Zidesamtinib, focusing on TKI-pre-treated patients who exhibit advanced ROS1-positive NSCLC.

The Future of Nuvalent

Nuvalent is committed to addressing the unmet needs in cancer therapeutics through precisely targeted therapies designed to overcome the limitations of existing treatments. The company boasts a diverse pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered NSCLC.

As they prepare for their presentations at this prestigious conference, Nuvalent's focus remains firmly aimed at innovative approaches to combat cancer effectively and improve patient outcomes. The results from these trials may pave the way for significant advancements in the treatment landscape of ROS1-positive NSCLC and inspire further research into targeted therapies.

For researchers, clinicians, and other stakeholders in the oncology community, the forthcoming presentations will be critical in understanding how Zidesamtinib could reshape the management of ROS1-positive cancers and improve the quality of life for affected patients.